Evotec

Evotec reports that the cost-saving program "Horizon" is progressing faster than planned and has already realized just over one-fifth of the savings expected by the end of 2027; the goal is to reduce the cost base by €75m and to close four plants with up to 800 job cuts (about half already carried out). The medium-term revenue forecast was lowered to around €1bn by 2030, though CEO Christian Wojczewski sees the potential for another billion if partner development improves. In the first nine months, revenue fell by about 13% to roughly €465m, adjusted EBITDA was -€44.3m and the net loss about €195m; full-year revenue is expected to be €570–610m. The stock is up more than 5% today and broke the 50-day line, but the company must continue to deliver to achieve a sustainable turnaround. » More on deraktionaer.de

Evotec is appointing Joanna Holbrook to the executive board and as chief scientific officer effective 1 November 2026; she brings more than 25 years of experience in omics, data sciences, novel therapeutics and precision medicine. Holbrook joins from Novo Nordisk, where she served, among other roles, as therapy area head for cardiovascular, renal and liver diseases and as head of in vitro discovery platforms. The appointment supported the stock in the short term, but for a sustainable turnaround Evotec must clearly improve profitability. » More on deraktionaer.de

Evotec reports revenue of 465.0 million euros and an adjusted negative EBITDA of 42.8 million euros for the first nine months, both better than analysts had expected. The management board leaves the July-lowered full-year guidance unchanged at 570–610 million euros in revenue and an adjusted EBITDA of -70 to -105 million euros. The share price rose by nearly seven percent after the figures, but remains substantially down year-to-date. » More on finanzen.net

Evotec stands by the annual forecast it lowered in mid‑July and expects revenue of €570 to €610 million. Adjusted EBITDA is forecast at between minus €70 million and minus €105 million. For the first nine months the company expects revenue of €465.0 million and adjusted EBITDA of minus €42.8 million, which is above current market expectations and is mainly attributed to the timing of consensus estimates. » More on finanzen.net

After a sharp share-price slump, EVOTEC stock is showing first signs of recovery but remains under pressure due to the sales forecast for 2026 being cut (€570–610m) and an expected adjusted EBITDA loss. The cost-saving program Horizon is intended to save around €75m annually from late 2027, but will cause one-off cash costs of about €100m and 800 job cuts in the near term. A current strategic review and personnel changes add uncertainty, although net order intake in the core business has risen and liquidity still appears solid for now. Investors should watch the next quarterly results, liquidity development and concrete progress on Horizon. » More on finanzen.net